IL2 and ovarian carcinoma: F16–IL2 has exhibited an excellent safety profile in cynomolgus monkeys and is currently being studied in two phase Ib clinical trials, in combination with doxorubicin (breast and ovarian cancer) or in combination with paclitaxel (breast and lung cancer).